PSC
HBIO icon

Piper Sandler & Co’s Harvard Bioscience HBIO Stock Holding History

Piper Sandler & Co’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-7,500
Closed -$437K – 109
2015
Q1 		$437K Buy
+7,500
New +$403K 0.18% 52

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Piper Sandler & Co's HBIO Position: Q2 2015 in Review

Piper Sandler & Co sold out of Harvard Bioscience (HBIO) in Q2 2015, closing a stake of 7,500 shares — an estimated $437K sold.

Piper Sandler & Co first reported a position in HBIO in Q1 2015 and held it in 1 quarter. The position peaked at $437K in Q1 2015. 84 funds tracked by Wall St. Rank hold HBIO as of Q2 2015.

  • Piper Sandler & Co reported no remaining Harvard Bioscience position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 7,500 Harvard Bioscience shares in Q2 2015, an estimated $437K.
  • Piper Sandler & Co first reported a position in Harvard Bioscience in Q1 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Harvard Bioscience position peaked at $437K in Q1 2015.
  • 84 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.